New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Businesswire49minutes ago

Fund Update: AMERIPRISE FINANCIAL INC Just Disclosed New Holdings

Quiver QuantitativeFeb 14 12:18 ET

Bristol-Myers Squibb's Melanoma Treatment Fails to Meet Primary Endpoint in Phase 3 Adjuvant Trial

MT NewswiresFeb 13 17:24 ET

Bristol-Myers Squibb: Disappointed in Outcome of RELATIVITY-098 Trial and That LAG-3 Inhibition in Adjuvant Setting Did Not Lead to Same Improved Efficacy Outcomes Seen in Advanced Melanoma >BMY

Dow JonesFeb 13 16:21 ET

Bristol-Myers Squibb: RELATIVITY-098 Trial Evaluating Opdualag for Treating Completely Resected Stage III-IV Melanoma Did Not Meet Primary Endpoint of Recurrence-Free Survival >BMY

Dow JonesFeb 13 16:21 ET

Wall Street Today: Trump Assigns Tariff Homework Study, Market Climbs

Kevin TraversFeb 13 16:20 ET